<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="178698">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00768716</url>
  </required_header>
  <id_info>
    <org_study_id>8600</org_study_id>
    <secondary_id>GM061834</secondary_id>
    <nct_id>NCT00768716</nct_id>
  </id_info>
  <brief_title>Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics</brief_title>
  <official_title>Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although acetaminophen is the most commonly used nonprescription drug in the USA, little is
      known regarding the influence of genes and race/ethnicity on acetaminophen disposition. The
      investigators long-term goal is to understand the causes of differences in acetaminophen
      disposition between people that are the result of genetic variation and ethnicity and may
      predispose individuals to a higher risk of acetaminophen hepatotoxicity. The aim of this
      particular study is to measure the rate of elimination of acetaminophen via the 3 main
      pathways (glucuronidation, sulfation and oxidation) in self-identified White-Americans
      (n=100) and African-Americans (n=100). These rates will then be correlated with selected
      genetic polymorphisms in genes encoding enzymes involved in acetaminophen metabolism. Two
      main hypotheses will be tested: 1. African-Americans eliminate acetaminophen more rapidly by
      glucuronidation than do White-Americans. 2. Elimination via glucuronidation, sulfation, and
      oxidation in subjects will be significantly correlated with the presence of polymorphisms in
      the UGT1A6, SULT1A1, and CYP2E1 genes, respectively.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">April 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acetaminophen plasma levels</measure>
    <time_frame>2 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acetaminophen metabolite levels</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pain</condition>
  <condition>Fever</condition>
  <condition>Hepatotoxicity</condition>
  <arm_group>
    <arm_group_label>White subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Black subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>2 x 500 mg oral once</description>
    <arm_group_label>White subjects</arm_group_label>
    <arm_group_label>Black subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  self-declared white/Caucasian

          -  self-declared African-American

          -  active

          -  ambulatory

          -  no evidence of medical disease

        Exclusion Criteria:

          -  alcohol use of 3 or more drinks per day

          -  HIV or hepatitis (B or C) infection

          -  isoniazid

          -  disulfiram

          -  phenobarbital

          -  phenytoin

          -  carbamazepine

          -  rifampicin

          -  valproic acid

          -  probenecid

          -  St. John's Wort
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael H Court, BVSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gina Masse</last_name>
    <phone>617-636-2192</phone>
    <email>gina.masse@tufts.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tufts Clinical Pharmacology Study Unit</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Masse</last_name>
      <phone>617-636-2192</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, Court MH. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 5'-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation. J Pharmacol Exp Ther. 2005 Jun;313(3):1331-9. Epub 2005 Mar 10.</citation>
    <PMID>15761114</PMID>
  </reference>
  <reference>
    <citation>Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, Court MH. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6. Epub 2005 Mar 10.</citation>
    <PMID>15761113</PMID>
  </reference>
  <reference>
    <citation>Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, Mackenzie PI. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther. 2001 Dec;299(3):998-1006.</citation>
    <PMID>11714888</PMID>
  </reference>
  <verification_date>October 2008</verification_date>
  <lastchanged_date>October 7, 2008</lastchanged_date>
  <firstreceived_date>October 7, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Dr Michael H. Court</name_title>
    <organization>Tufts University</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
